Table 2 Univariate and multivariate analysis of the prognostic value of clinicopathological features in ER+/HER2- patients using Cox proportional hazard modeling in the TCGA dataset
Dependent | No. | HR (univariable) | HR (multivariable) |
|---|---|---|---|
Subtype | |||
ER+/PR-/HER2- | 60 | - | - |
ER+/PR+/HER2- | 409 | 0.65 (0.34–1.25, p = 0.196) | 0.77 (0.21–2.84, p = 0.697) |
Age | |||
70+ | 100 | - | - |
50–69 | 249 | 0.60 (0.34–1.05, p = 0.075) | 0.21 (0.08–0.57, p = 0.002) |
35–49 | 107 | 0.26 (0.12–0.57, p = 0.001) | 0.05 (0.01–0.22, p < 0.001) |
< 35 | 13 | 1.05 (0.31–3.57, p = 0.941) | 0.00 (0.00-Inf, p = 0.999) |
AJCC Stage | |||
Stage I | 92 | - | - |
Stage II | 249 | 1.45 (0.66–3.18, p = 0.354) | 8.22 (1.55–43.47, p = 0.013) |
Stage III | 105 | 1.75 (0.74–4.15, p = 0.200) | 6.55 (0.47–92.01, p = 0.163) |
Stage IV | 12 | 7.58 (2.90-19.79, p < 0.001) | 133.80 (4.74-3775.01, p = 0.004) |
Histology | |||
IDC | 362 | - | - |
ILC | 60 | 0.69 (0.29–1.61, p = 0.387) | 1.35 (0.32–5.71, p = 0.682) |
Mixed Histology | 20 | 0.82 (0.29–2.27, p = 0.700) | 2.06 (0.39–10.89, p = 0.396) |
Others | 27 | 1.29 (0.55–3.04, p = 0.562) | 1.14 (0.16–7.96, p = 0.893) |
pT | |||
T1 | 138 | - | - |
T2 | 256 | 1.30 (0.70–2.38, p = 0.406) | 0.27 (0.07–1.03, p = 0.055) |
T3 | 54 | 0.92 (0.38–2.18, p = 0.844) | 0.05 (0.01–0.39, p = 0.005) |
T4 | 20 | 3.41 (1.42–8.23, p = 0.006) | 0.08 (0.01–1.05, p = 0.055) |
pN | |||
N0 | 219 | - | - |
N1 | 157 | 1.58 (0.89–2.82, p = 0.117) | 1.13 (0.32–3.92, p = 0.850) |
N2 | 61 | 2.14 (1.03–4.45, p = 0.042) | 3.42 (0.38–30.62, p = 0.271) |
N3 | 24 | 2.20 (0.75–6.44, p = 0.149) | 0.36 (0.04–3.52, p = 0.382) |
PAM50 | |||
Luminal A | 193 | - | - |
Luminal B | 99 | 1.89 (1.02–3.51, p = 0.044) | 3.09 (0.97–9.85, p = 0.057) |
Basal-like | 10 | 0.62 (0.15–2.61, p = 0.511) | 8.21 (0.95–71.15, p = 0.056) |
HER2-enriched | 10 | 3.83 (1.14–12.84, p = 0.030) | 20.69 (3.20-133.85, p = 0.001) |
Normal-like | 6 | 0.00 (0.00-Inf, p = 0.997) | 0.00 (0.00-Inf, p = 0.999) |
Methylation Cluster | |||
Cluster 1 | 88 | - | - |
Cluster 2 | 133 | 1.55 (0.75–3.19, p = 0.239) | 0.89 (0.28–2.88, p = 0.852) |
Cluster 3 | 49 | 0.85 (0.27–2.67, p = 0.780) | 0.34 (0.05–2.48, p = 0.287) |
Cluster 4 | 168 | 1.70 (0.84–3.44, p = 0.142) | 0.87 (0.29–2.65, p = 0.813) |
Cluster 5 | 28 | 0.22 (0.03–1.71, p = 0.148) | 0.00 (0.00-Inf, p = 0.997) |
CN Cluster | |||
Cluster 1 | 59 | - | - |
Cluster 2 | 174 | 0.73 (0.36–1.48, p = 0.381) | 0.26 (0.08–0.90, p = 0.033) |
Cluster 3 | 84 | 0.50 (0.20–1.21, p = 0.124) | 0.07 (0.01–0.35, p = 0.001) |
Cluster 4 | 80 | 0.72 (0.33–1.58, p = 0.410) | 0.07 (0.01–0.40, p = 0.003) |
Cluster 5 | 61 | 0.90 (0.38–2.14, p = 0.810) | 0.24 (0.05–1.17, p = 0.077) |
miRNA Cluster | |||
Cluster 1 | 33 | - | - |
Cluster 2 | 78 | 0.62 (0.22–1.73, p = 0.363) | 0.22 (0.03–1.56, p = 0.130) |
Cluster 3 | 22 | 0.40 (0.08–1.92, p = 0.250) | 0.03 (0.00-0.72, p = 0.030) |
Cluster 4 | 120 | 0.63 (0.26–1.53, p = 0.308) | 0.39 (0.10–1.63, p = 0.200) |
Cluster 5 | 40 | 1.00 (0.36–2.77, p = 1.000) | 1.96 (0.33–11.82, p = 0.461) |
Cluster 6 | 92 | 0.64 (0.26–1.56, p = 0.330) | 0.58 (0.11–3.06, p = 0.524) |
Cluster 7 | 39 | 0.55 (0.17–1.74, p = 0.308) | 0.38 (0.04–3.66, p = 0.403) |